用JAK1/2抑制剂治疗的骨髓纤维化患者的能量消耗
Douglas Tremblay1, Mikaela Dougherty1, John Mascarenhas1
1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Frontiers in endocrinology
|July 17, 2023
概括
针对骨髓纤维化症的鲁克索利提尼布治疗可能会导致体重增加. 这项试点研究表明,总体能源消耗的变化,而不仅仅是食欲,可能会导致这种常见的副作用.
科学领域:
- 血液学 血液学 血液学
- 代谢医学是一种代谢医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 体重增加是卢克索利提尼布的一种已知的不良影响,鲁克索利提尼布是一种Janus 激酶 (JAK) 1/2抑制剂.
- 鲁克索利提尼布是治疗骨髓纤维化的主要治疗方法,该疾病影响血液细胞的生产.
- 驱动鲁克索利提尼布诱导的体重增加的确切机制尚未完全理解,理论包括减少脂肪分解和改变食欲调节.
研究的目的:
- 为了研究与骨髓纤维化患者的鲁克索利提尼布治疗相关的代谢变化.
- 评估使用便携式间接热量计来测量该患者群体的能量消耗的可行性.
- 探索ruxolitinib治疗与全身能量消耗的变化之间的关系.
主要方法:
- 进行了一项试点研究,涉及接受 ruxolitinib 治疗的骨髓纤维化患者.
- 便携式间接热量计被用来量化静止能量消耗.
- 在一小群患者中,在ruxolitinib治疗前和治疗期间进行了测量.
主要成果:
- 在这项研究中,这两名患者在接受鲁克索利提尼布治疗期间腰围增加.
- 能源支出模式最初呈现上升,随后下降,随后上升至低于基线水平.
- 在 ruxolitinib 治疗期间,两名患者的腰围都增加了.
结论:
- 与ruxolitinib治疗相关的体重增加可能与全身能量消耗的改变有关.
- 便携式间接热量计似乎是可行的研究在ruxolitinib治疗的骨髓纤维化患者的代谢变化.
- 需要进一步的研究来阐明精确的代谢途径,涉及到ruxolitinib诱导的体重增加.
更多相关视频
相关概念视频
01:20The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
202
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
202
01:22Bone Marrow Sampling and Transplants
360
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
360
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
209
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
209
01:11Renal Failure: Dose Adjustments
123
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
123
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K